Novel First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
- Gabriella Gobbi, McGill University
Membres de l'équipe :
- Mark Ware, McGill University
- Robert Zamboni, McGill University
- Stefano Comai, McGill University
- McGill University
- Delmar Chemicals Inc.
Aperçu du projet
Neuropathic pain is a chronic pain disorder resulting from damage to the nerves. It may be due to cancer, diabetes or conditions like fibromyalgia. Neuropathic pain is often eased by antidepressant or anti-epileptic medicines but most often treated with opioids. Opioid use is associated with serious adverse effects such as addiction and death by overdose. Research on novel analgesic drugs for the treatment of neuropathic pain is thus apriority. Gabriella Gobbi and her team at their laboratory at McGill University have previously designed, synthesized and validated a novel analgesic drug in animal models that may be beneficial in treating neuropathic pain in humans without the side effects that usually occur with opioids. In this project, they will be able to conduct essential pharmacological and toxicological studies and submit an Investigational New Drug (IND) application to obtain the required permission from the regulatory authorities to begin human clinical testing.